CYTK · Cytokinetics Inc
Price
Snapshot
50 fields · last close| Market Cap | $9.56B |
| P/E | — |
| Float | 132.0M |
| Beta | 0.40 |
| Volatility | 10.0% |
| Exchange | NASDAQ |
| Sector | Biotechnology |
| Cap tier | Mid cap |
| Macro sensitivity | Low |
| Clavix score | 75 |
| Price | 67.74 |
| Change | −1.51% |
| Prev Close | 68.78 |
| Open | 70.18 |
| Day Low | 68.15 |
| Day High | 70.18 |
| Avg Vol | 2 |
| Avg $ Vol | $139.3M |
| 52W High | 88.31 |
| 52W Low | 47.22 |
| 52W Pos | 49.9% |
| From High | −23.29% |
| From Low | +43.46% |
| Max DD 1Y | −21.18% |
| Spread | 0.10% |
| Liquidity | Normal |
| SMA 20 | −7.72% |
| SMA 50 | −11.74% |
| SMA 200 | −3.24% |
| RSI (14) | 35.1 |
| Vol 30D | 38.8% |
| Vol 90D | 37.1% |
| 1Y Range | 47–88 |
| Daily bars | 516 |
| Perf Week | −6.76% |
| Perf Month | −11.53% |
| Perf Quarter | −12.69% |
| Perf Half Y | +9.26% |
| Perf Year | +44.62% |
| Perf YTD | +9.74% |
| Prev Day | −1.51% |
| Clavix | B |
| Debt / Eq | 0.59 |
| Curr Ratio | 4.53 |
| Int Cover | -10.7× |
| FCF Margin | 79.8% |
| Rev Growth | −57.1% |
| Profit | Unprofitable |
| Leverage | Low |
| Sector rank | 13 / 35 |
Clavix risk grade
regraded every trading dayCYTK grades B, 75 of 100. Steadiest on Macro Resilience (69), most exposed on Price Stability (59, mixed). 4 of the 4 weighted dimensions sit above the Biotechnology median. Ranks 13 of 35 in Biotechnology by Clavix score.
How rough the ride is
| CYTK | Biotechnology median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 0.40 | 0.51 |
| Volatilityannualized | 10.0% | 13.4% |
| Max drawdown, past yearworst peak-to-trough fall | −21.2% | — |
| Typical daily movemedian absolute daily change | 1.51% | — |
| Days beyond ±3%of the last 252 sessions | 5723% | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| CYTK | Biotechnology median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 0.40 | 0.51 |
| Macro sensitivityrate, dollar and credit exposure bucket | Low | Low56% of 36 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Biotechnology names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| CYTK | |
|---|---|
| 1 week | −6.8% |
| 1 month | −11.5% |
| Year to date | +9.7% |
| 1 year | +44.6% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| CYTK | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30since 22 Aug |
| Average score0 most bearish, 100 most bullish | 68 |
| Bullish · bearisharticles above 60 · below 40 | 22 · 2 |
| Directionarticles whose tone is improving vs worsening | 22 ↑ 2 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 36 Biotechnology names Clavix covers; the tick is the sector median.
Growth
| CYTK | |
|---|---|
| Revenue growthyear over year | −57.1% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Biotechnology median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openCytokinetics CEO Robert Blum sold 97,926 shares on September 15th at an average price of $69.33, totaling about $6.79 million and reducing his ownership stake in the company by 20.26%. After the sale, he still holds 385,320 shares worth about $26.7 million. The sale was executed under a pre-arranged Rule 10b5-1 trading plan, which is a trading schedule set up in advance (typically when the insider does not have material non-public information) that allows executives to sell shares on preset dates.
Cytokinetics' stock remains under pressure, but its drug Myqorzo posted $25.3 million in sales in the second quarter, up 427% from the previous quarter, even while competing against Bristol Myers Squibb's Camzyos. On August 28, the New England Journal of Medicine published full Phase 3 data showing Myqorzo was highly effective in treating symptomatic nonobstructive HCM (a heart muscle thickening condition without blocked blood flow), an area where Camzyos failed.
CalSTRS, the California State Teachers Retirement System, reported buying 10,765,080 shares of Cytokinetics (CYTK) during the second quarter, raising its total position to 10,901,679 shares, a 7,880.8% increase over what it held before.
A Cytokinetics director, Robert Landry, sold 1,000 shares at an average price of $74.66, bringing in roughly $74,660 and reducing his stake by about 9.8% to 9,184 shares. The sale was carried out under a pre-arranged Rule 10b5-1 trading plan, which is a schedule insiders set up in advance to sell shares at preset times so they can avoid any suggestion of trading on non-public information.
An RBC Capital Markets analyst said Cytokinetics likely has the upper hand in its ongoing patent dispute with Bristol-Myers Squibb. The article provides no further detail on the dispute or the analyst's reasoning.
Nearest peers by size
Biotechnology| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| ARWR | Arrowhead Pharmaceuticals Inc | C+ | $9.39B | — | 1.33 | Compare |
| PTGX | Protagonist Therapeutics Inc | B | $9.25B | 111.61 | 1.18 | Compare |
| KRYS | Krystal Biotech Inc | B | $9.97B | 41.27 | 0.56 | Compare |
| SYRE | Spyre Therapeutics Inc | — | $8.87B | — | 2.95 | Compare |
| TGTX | TG Therapeutics Inc | B- | $8.71B | 19.72 | 1.90 | Compare |
| CAI | Caris Life Sciences Inc | C | $8.47B | 80.58 | 0.39 | Compare |
| TWST | Twist Bioscience Corp | D+ | $10.99B | — | 2.23 | Compare |
| MDGL | Madrigal Pharmaceuticals Inc | B | $12.28B | — | -1.09 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. Three months free on iPhone.